,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,72129,221493,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,1376,1,2,,47193710,221493,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
7,1385,2,2,,47193710,221493,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
8,1422,1,1,,47193710,221493,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
9,1465,1,1,,47193710,221493,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
10,1511,1,3,,47193710,221493,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
11,1529,1,1,,47193710,221493,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
12,1530,1,1,,47193710,221493,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
13,1531,1,1,,47193710,221493,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
14,1532,1,1,,47193710,221493,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
15,1554,1,1,,47193710,221493,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
16,1621,1,2,,47193710,221493,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
17,1626,1,2,,47193710,221493,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
18,1662,1,2,,47193710,221493,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
19,1663,1,2,,47193710,221493,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
20,1672,1,3,,47193710,221493,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
21,1813,1,2,,47193710,221493,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
22,1814,1,2,,47193710,221493,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
23,1832,2,1,,47193710,221493,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
24,1850,2,1,,47193710,221493,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
25,1863,2,1,,47193710,221493,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
26,1875,2,1,,47193710,221493,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
27,1885,2,1,,47193710,221493,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
28,1899,1,3,,47193710,221493,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
29,1903,2,3,,47193710,221493,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
30,1906,1,3,,47193710,221493,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
31,1910,1,2,,47193710,221493,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
32,1947,1,2,,47193710,221493,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
33,1950,1,3,,47193710,221493,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
34,1956,1,1,,47193710,221493,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
35,1962,1,2,,47193710,221493,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
36,1974,1,2,,47193710,221493,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
37,1979,1,1,,47193710,221493,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
38,1987,1,2,,47193710,221493,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
39,2016,1,3,,47193710,221493,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
40,2023,1,3,,47193710,221493,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
41,2025,1,3,,47193710,221493,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
42,2029,1,3,,47193710,221493,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
43,2052,2,1,,47193710,221493,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
44,2057,1,2,,47193710,221493,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
45,2066,1,4,,47193710,221493,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
46,2094,1,2,,47193710,221493,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
47,2094,1,2,,47193710,221493,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
48,2094,1,2,,47193710,221493,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
49,2097,1,2,,47193710,221493,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
50,2098,1,1,,47193710,221493,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
51,2099,1,1,,47193710,221493,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
52,2129,1,2,,47193710,221493,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
53,2130,1,3,,47193710,221493,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
54,2156,2,2,,47193710,221493,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
55,2174,1,3,,47193710,221493,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
56,2177,1,3,,47193710,221493,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
57,2216,1,3,,47193710,221493,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
58,2221,1,2,,47193710,221493,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
59,2227,1,2,,47193710,221493,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
60,2234,1,2,,47193710,221493,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
61,2235,1,2,,47193710,221493,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
62,2237,1,2,,47193710,221493,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
63,2239,1,2,,47193710,221493,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
64,2247,1,2,,47193710,221493,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
65,2280,2,3,,47193710,221493,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
66,2300,1,3,,47193710,221493,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
67,2380,1,2,,47193710,221493,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
68,2391,1,1,,47193710,221493,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
69,2435,1,2,,47193710,221493,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
70,2445,1,2,,47193710,221493,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
71,2462,1,1,,47193710,221493,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
72,2462,1,1,,47193710,221493,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
73,2520,1,4,,47193710,221493,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
74,2521,1,3,,47193710,221493,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
75,2524,1,2,,47193710,221493,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
76,2540,1,2,,47193710,221493,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
77,2544,1,2,,47193710,221493,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
78,2550,1,3,,47193710,221493,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
79,2553,1,2,,47193710,221493,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
80,2557,1,3,,47193710,221493,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
81,2563,1,1,,47193710,221493,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
82,2599,1,2,,47193710,221493,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
83,2606,1,2,,47193710,221493,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
84,2629,1,1,,47193710,221493,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
85,2642,1,2,,47193710,221493,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
86,2648,1,2,,47193710,221493,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
87,2650,2,1,,47193710,221493,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
88,2661,1,1,,47193710,221493,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
89,2690,1,2,,47193710,221493,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
90,2716,1,1,,47193710,221493,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
91,2717,1,2,,47193710,221493,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
92,2718,1,1,,47193710,221493,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
93,2751,2,2,,47193710,221493,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
94,2796,1,4,,47193710,221493,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
95,2797,1,2,,47193710,221493,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
96,2805,2,2,,47193710,221493,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
97,2806,2,2,,47193710,221493,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
98,2825,1,2,,47193710,221493,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
99,54340,3,3,,103484622,221493,Unspecified,,,,,Binding constant towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade,Other,14643314.0,
100,54341,3,3,,103484622,221493,Unspecified,,,,,Sensitivity value towards cyclodextrin conjugated peptide (with pyrene) at 25 degrees Centigrade,Other,14643314.0,
101,165380,6,2,,103484622,221493,Unspecified,,,83.0,IC50,"The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 50%",Confirmatory,8151614.0,
102,165385,7,1,,103484622,221493,Unspecified,,,,,"The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 75%",Other,8151614.0,
103,167640,7,1,,103484622,221493,Active,,,,,"The compound was evaluated for the inhibition of Na+-dependent [3H]taurocholate uptake into ileal brush border membrane vesicles in rabbit, by 25%",Other,8151614.0,
104,167719,7,1,,103484622,221493,Active,,,,,Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles,Other,7932551.0,
105,167720,6,2,,103484622,221493,Unspecified,,,83.0,IC50,Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles,Confirmatory,7932551.0,
106,167721,7,1,,103484622,221493,Unspecified,,,,,Tested for inhibition of Na+ -dependent [3H]taurocholate uptake into rabbit ileal brush border membrane vesicles,Other,7932551.0,
107,263154,3,3,,103484622,221493,Inactive,,,,,Induction of HIV1 NL4-3 virus replication in CEM-GFP cells,Other,16610808.0,
108,283558,11,1,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs,Other,17210767.0,
109,283559,11,1,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB after 24 hrs,Other,17210767.0,
110,283560,11,1,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli HNCE4 after 24 hrs,Other,17210767.0,
111,283561,3,4,,103484622,221493,Active,,,,,Effect on modulation in uptake of [3H]progesterone in Escherichia coli AG102 with marR1 mutation,Other,17210767.0,
112,283564,3,4,,103484622,221493,Active,,,,,Effect on uptake of [3H]estradiol in Escherichia coli AG102 with functional AcrAB-TolC system,Other,17210767.0,
113,283565,3,4,,103484622,221493,Active,,,,,Effect on uptake of [3H]estradiol in Escherichia coli CE1 with functional AcrAB-TolC system,Other,17210767.0,
114,297449,3,7,,103484622,221493,Unspecified,74762624.0,151306.0,,,Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to lithocholic acid,Other,17685603.0,
115,297450,7,1,,103484622,221493,Active,74762624.0,151306.0,13.6,EC50,Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay,Confirmatory,17685603.0,
116,297451,7,6,,103484622,221493,Inconclusive,46577705.0,9971.0,,EC50,Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay,Confirmatory,17685603.0,
117,297452,4,10,,103484622,221493,Inconclusive,46577705.0,9971.0,,,Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay relative to 6ECDCA,Other,17685603.0,
118,297453,3,5,,103484622,221493,Inconclusive,,,,,Ratio of EC50 for TGR5 expressed in CHO cells to EC50 for FXR expressed in COS1 cells,Other,17685603.0,
119,324923,7,6,,103484622,221493,Active,74762624.0,151306.0,13.6,EC50,Agonist activity at human TGR5 expressed in CHO cells by luciferase assay,Confirmatory,18307294.0,
120,324924,3,10,,103484622,221493,Unspecified,74762624.0,151306.0,,,Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid,Other,18307294.0,
121,346025,3,3,,103484622,221493,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
122,388081,7,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Candida albicans,Other,18805690.0,
123,388082,7,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Cryptococcus neoformans,Other,18805690.0,
124,388083,7,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Benjaminiella poitrasii,Other,18805690.0,
125,388084,7,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Yarrowia lipolytica,Other,18805690.0,
126,388085,7,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Fusarium oxysporum,Other,18805690.0,
127,388086,7,2,,103484622,221493,Unspecified,,,,,Antibacterial activity at Escherichia coli,Other,18805690.0,
128,388087,7,2,,103484622,221493,Unspecified,,,,,Antibacterial activity at Staphylococcus aureus,Other,18805690.0,
129,388088,6,2,,103484622,221493,Unspecified,,,,,Antifungal activity at Candida albicans assessed as concentration required to lower the MIC of fluconazole from 32 to 1 ug/mL after 48 hrs,Other,18805690.0,
130,388089,6,2,,103484622,221493,Unspecified,,,,,Antibacterial activity at Escherichia coli assessed as concentration required to lower the MIC of erythromycin from 64 to 1 ug/mL after 24 hrs,Other,18805690.0,
131,388090,6,2,,103484622,221493,Unspecified,,,50.0,IC50,Antiproliferative activity against human MCF7 cells by MTT assay,Confirmatory,18805690.0,
132,388091,6,2,,103484622,221493,Unspecified,,,1000.0,IC50,Antiproliferative activity against HEK293 cells by MTT assay,Confirmatory,18805690.0,
133,404304,3,10,,103484622,221493,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
134,422543,3,10,,103484622,221493,Unspecified,129404.0,5319.0,,,"Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate",Other,19102680.0,
135,422544,3,10,,103484622,221493,Unspecified,129404.0,5319.0,,,"Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate",Other,19102680.0,
136,422547,3,10,,103484622,221493,Inactive,129404.0,5319.0,,,"Activation of human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles",Other,19102680.0,
137,422551,10,5,,103484622,221493,Unspecified,129404.0,5319.0,150.0,Kd,Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli by resonance energy transfer assay in presence of trimethyl-ammonium-diphenylhexatriene,Confirmatory,19102680.0,
138,422552,3,10,,103484622,221493,Active,129404.0,5319.0,,,Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli at 100 uM by saturation transfer difference NMR spectroscopy,Other,19102680.0,
139,422553,3,3,,103484622,221493,Active,,,,,Binding affinity to pig PLA2 at 100 uM by saturation transfer difference NMR spectroscopy,Other,19102680.0,
140,422554,3,11,,103484622,221493,Unspecified,46577705.0,9971.0,,,Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control,Other,19102680.0,
141,422555,3,11,,103484622,221493,Unspecified,46577705.0,9971.0,,,Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate,Other,19102680.0,
142,434955,1,2,,47193710,221493,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
143,434962,1,2,,47193710,221493,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
144,434973,1,3,,47193710,221493,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
145,434989,1,1,,47193710,221493,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
146,435003,1,3,,47193710,221493,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
147,435005,1,1,,47193710,221493,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
148,435022,2,2,,47193710,221493,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
149,435030,1,2,,47193710,221493,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
150,435030,1,2,,47193710,221493,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
151,441572,8,3,,103484622,221493,Unspecified,,,100.0,EC50,Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay,Confirmatory,20014870.0,
152,441573,9,6,,103484622,221493,Active,74762624.0,151306.0,13.6,EC50,Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay,Confirmatory,20014870.0,
153,441574,3,6,,103484622,221493,Unspecified,,,,,Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay relative to INT-747,Other,20014870.0,
154,441575,3,10,,103484622,221493,Unspecified,74762624.0,151306.0,,,Agonist activity at human TGR5 expressed in CHO cells assessed as increase in CRE-driven gene expression by luciferase reporter gene assay relative to lithocholic acid,Other,20014870.0,
155,441576,6,2,,103484622,221493,Unspecified,,,,,Solubility in 0.1M HCl water solution,Other,20014870.0,
156,441577,3,3,,103484622,221493,Unspecified,,,,,Critical micellar concentration in 0.15 M NaCl water solution,Other,20014870.0,
157,441578,3,7,,103484622,221493,Unspecified,,,,,Binding affinity to albumin,Other,20014870.0,
158,441579,7,1,,103484622,221493,Unspecified,,,,,Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr,Other,20014870.0,
159,441580,7,1,,103484622,221493,Unspecified,,,,,Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg administered intraduodenally over 1 hr,Other,20014870.0,
160,441581,8,1,,103484622,221493,Unspecified,,,,,"Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg, iv over 1 hr",Other,20014870.0,
161,441582,8,1,,103484622,221493,Unspecified,,,,,"Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg, iv over 1 hr",Other,20014870.0,
162,441583,8,1,,103484622,221493,Unspecified,,,,,Cholerectic effect in bile fistula rat model assessed as maximum bile secretion rate at 1 umol/min/kg administered intraduodenally over 1 hr,Other,20014870.0,
163,441584,8,1,,103484622,221493,Unspecified,,,,,Cholerectic effect in bile fistula rat model assessed as maximum bile acids secretion rate per kg body weight at 1 umol/min/kg administered intraduodenally over 1 hr,Other,20014870.0,
164,441585,7,1,,103484622,221493,Unspecified,,,,,"Metabolic stability in bile fistula rat model assessed as intact drug level recovered in bile at 1 umol/min/kg, iv over 1 hr",Other,20014870.0,
165,441586,7,1,,103484622,221493,Unspecified,,,,,"Metabolic stability in bile fistula rat model assessed as conjugated drug level recovered in bile at 1 umol/min/kg, iv over 1 hr",Other,20014870.0,
166,441588,3,3,,103484622,221493,Unspecified,,,,,Metabolic stability in human stool broth culture assessed as 7-dehydroxylation of compound after 1 hr,Other,20014870.0,
167,441589,3,3,,103484622,221493,Unspecified,,,,,Metabolic stability in human stool broth culture assessed as 7-dehydroxylation of compound after 8 hrs,Other,20014870.0,
168,449728,1,2,,47193710,221493,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
169,449739,1,2,,47193710,221493,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
170,449762,1,2,,47193710,221493,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
171,449763,1,3,,47193710,221493,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
172,449768,1,1,,47193710,221493,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
173,463079,1,2,,47193710,221493,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
174,463082,1,1,,47193710,221493,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
175,463104,1,2,,47193710,221493,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
176,463111,1,1,,47193710,221493,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
177,463141,1,2,,47193710,221493,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
178,463165,1,1,,47193710,221493,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
179,463190,1,2,,47193710,221493,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
180,463195,1,2,,47193710,221493,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
181,463210,1,2,,47193710,221493,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
182,463212,1,1,,47193710,221493,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
183,485270,1,1,,47193710,221493,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
184,485272,1,1,,47193710,221493,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
185,485273,2,1,,47193710,221493,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
186,485275,1,3,,47193710,221493,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
187,485317,1,2,,47193710,221493,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
188,485346,1,1,,47193710,221493,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
189,485346,1,1,,47193710,221493,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
190,486729,6,2,,103484622,221493,Unspecified,,,,,Antimicrobial activity against Escherichia coli after 24 hrs,Other,20181416.0,
191,486730,6,2,,103484622,221493,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa after 24 hrs,Other,20181416.0,
192,486731,6,2,,103484622,221493,Inactive,,,,,Antimicrobial activity against Enterobacter aerogenes after 24 hrs,Other,20181416.0,
193,486732,6,2,,103484622,221493,Inactive,,,,,Antimicrobial activity against Staphylococcus aureus after 24 hrs,Other,20181416.0,
194,486733,6,2,,103484622,221493,Unspecified,,,,,Antimicrobial activity against Enterococcus faecalis after 24 hrs,Other,20181416.0,
195,486734,6,2,,103484622,221493,Inactive,,,,,Antimicrobial activity against Bacillus megaterium after 24 hrs,Other,20181416.0,
196,488839,1,1,,47193710,221493,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
197,488839,1,1,,47193710,221493,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
198,488847,1,3,,47193710,221493,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
199,488862,1,1,,47193710,221493,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
200,488890,1,2,,47193710,221493,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
201,488895,1,2,,47193710,221493,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
202,488896,1,1,,47193710,221493,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
203,488899,1,1,,47193710,221493,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
204,488922,1,2,,47193710,221493,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
205,488965,1,2,,47193710,221493,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
206,488966,1,1,,47193710,221493,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
207,488975,1,2,,47193710,221493,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
208,488977,1,2,,47193710,221493,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
209,489030,2,1,,47193710,221493,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
210,489031,2,1,,47193710,221493,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
211,490121,5,3,,103484622,221493,Unspecified,,,50.0,IC50,Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay,Confirmatory,20381215.0,
212,490122,5,2,,103484622,221493,Unspecified,,,50.0,IC50,Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay,Confirmatory,20381215.0,
213,490123,5,2,,103484622,221493,Unspecified,,,50.0,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay,Confirmatory,20381215.0,
214,490124,3,3,,103484622,221493,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,20381215.0,
215,492953,1,1,,47193710,221493,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
216,492956,1,1,,47193710,221493,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
217,492972,1,1,,47193710,221493,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
218,493005,1,1,,47193710,221493,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
219,493008,1,1,,47193710,221493,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
220,493008,1,1,,47193710,221493,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
221,493008,1,1,,47193710,221493,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
222,493008,1,1,,47193710,221493,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
223,493011,1,1,,47193710,221493,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
224,493012,1,1,,47193710,221493,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
225,493036,1,2,,47193710,221493,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
226,493087,1,1,,47193710,221493,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
227,493091,1,1,,47193710,221493,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
228,493098,1,1,,47193710,221493,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
229,493131,1,1,,47193710,221493,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
230,493160,1,1,,47193710,221493,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
231,493187,1,2,,47193710,221493,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
232,493244,1,1,,47193710,221493,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
233,493244,1,1,,47193710,221493,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
234,493244,1,1,,47193710,221493,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
235,493244,1,1,,47193710,221493,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
236,504326,1,2,,47193710,221493,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
237,504326,1,2,,47193710,221493,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
238,504329,1,1,,47193710,221493,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
239,504339,1,1,,47193710,221493,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
240,504357,1,1,,47193710,221493,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
241,504357,1,1,,47193710,221493,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
242,504406,1,1,,47193710,221493,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
243,504408,2,1,,47193710,221493,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
244,504411,1,1,,47193710,221493,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
245,504414,1,1,,47193710,221493,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
246,504414,1,1,,47193710,221493,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
247,504423,1,1,,47193710,221493,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
248,504441,1,1,,47193710,221493,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
249,504444,1,1,,47193710,221493,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
250,504454,1,3,,47193710,221493,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
251,504462,1,1,,47193710,221493,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
252,504490,1,2,,47193710,221493,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
253,504523,1,1,,47193710,221493,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
254,504523,1,1,,47193710,221493,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
255,504558,1,1,,47193710,221493,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
256,504577,2,2,,47193710,221493,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
257,504582,2,1,,47193710,221493,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
258,504634,1,1,,47193710,221493,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
259,504648,1,1,,47193710,221493,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
260,504690,1,3,,47193710,221493,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
261,504692,2,2,,47193710,221493,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
262,504700,1,1,,47193710,221493,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
263,504700,1,1,,47193710,221493,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
264,504707,1,1,,47193710,221493,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
265,504707,1,1,,47193710,221493,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
266,504720,1,1,,47193710,221493,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
267,504734,1,1,,47193710,221493,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
268,504766,2,1,,47193710,221493,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
269,504775,1,1,,47193710,221493,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
270,504803,1,1,,47193710,221493,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
271,504845,1,1,,47193710,221493,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
272,504847,1,1,,47193710,221493,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
273,504884,1,2,,47193710,221493,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
274,504891,1,1,,47193710,221493,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
275,504894,1,1,,47193710,221493,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
276,504937,1,2,,47193710,221493,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
277,510559,5,2,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB,Other,20038628.0,
278,510747,5,2,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene,Other,20038628.0,
279,510748,5,2,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene,Other,20038628.0,
280,510749,5,2,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene,Other,20038628.0,
281,510750,5,2,,103484622,221493,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene,Other,20038628.0,
282,515398,4,3,,103484622,221493,Unspecified,,,1075.0,CC50,Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,20713311.0,
283,515399,2,5,,103484622,221493,Unspecified,,,,,Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control,Other,20713311.0,
284,515400,2,5,,103484622,221493,Unspecified,,,,,Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control,Other,20713311.0,
285,516780,5,6,,103484622,221493,Active,74762624.0,151306.0,6.0,IC50,Agonist activity at human TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level,Confirmatory,20801037.0,
286,516781,5,1,,103484622,221493,Active,81912698.0,227289.0,5.3,IC50,Agonist activity at mouse TGR5 receptor expressed in HEK293 cells assessed as intracellular cAMP level,Confirmatory,20801037.0,
287,540253,1,1,,47193710,221493,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
288,540253,1,1,,47193710,221493,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
289,540253,1,1,,47193710,221493,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
290,540263,1,1,,47193710,221493,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
291,540263,1,1,,47193710,221493,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
292,540267,1,1,,47193710,221493,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
293,540295,1,1,,47193710,221493,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
294,540303,1,1,,47193710,221493,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
295,540303,1,1,,47193710,221493,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
296,540303,1,1,,47193710,221493,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
297,540308,1,1,,47193710,221493,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
298,540317,1,1,,47193710,221493,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
299,540336,1,1,,47193710,221493,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
300,540336,1,1,,47193710,221493,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
301,540364,1,2,,47193710,221493,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
302,588334,1,1,,47193710,221493,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
303,588335,1,1,,47193710,221493,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
304,588352,1,2,,47193710,221493,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
305,588354,1,1,,47193710,221493,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
306,588358,1,2,,47193710,221493,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
307,588405,1,1,,47193710,221493,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
308,588413,1,2,,47193710,221493,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
309,588436,1,1,,47193710,221493,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
310,588453,1,1,,47193710,221493,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
311,588456,1,1,,47193710,221493,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
312,588458,1,1,,47193710,221493,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
313,588473,1,1,,47193710,221493,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
314,588473,1,1,,47193710,221493,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
315,588475,1,2,,47193710,221493,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
316,588475,1,2,,47193710,221493,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
317,588478,1,2,,124812307,221493,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
318,588489,1,1,,47193710,221493,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
319,588492,1,1,,47193710,221493,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
320,588493,1,2,,47193710,221493,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
321,588497,1,2,,47193710,221493,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
322,588497,1,2,,47193710,221493,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
323,588497,1,2,,47193710,221493,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
324,588499,1,3,,47193710,221493,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
325,588499,1,3,,47193710,221493,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
326,588499,1,3,,47193710,221493,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
327,588501,1,2,,47193710,221493,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
328,588501,1,2,,47193710,221493,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
329,588501,1,2,,47193710,221493,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
330,588511,1,2,,47193710,221493,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
331,588549,1,1,,47193710,221493,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
332,588579,1,1,,47193710,221493,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
333,588590,1,1,,47193710,221493,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
334,588591,1,1,,47193710,221493,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
335,588621,1,1,,47193710,221493,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
336,588627,1,1,,47193710,221493,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
337,588664,1,2,,47193710,221493,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
338,588664,1,2,,47193710,221493,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
339,588674,1,2,,47193710,221493,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
340,588675,1,1,,47193710,221493,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
341,588676,1,1,,47193710,221493,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
342,588689,1,1,,47193710,221493,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
343,588692,2,1,,47193710,221493,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
344,588726,1,2,,47193710,221493,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
345,588727,1,1,,47193710,221493,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
346,588795,1,1,,47193710,221493,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
347,588814,1,3,,47193710,221493,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
348,588819,1,4,,47193710,221493,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
349,588832,1,1,,47193710,221493,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
350,588850,1,1,,47193710,221493,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
351,588852,1,3,,47193710,221493,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
352,588855,1,1,,47193710,221493,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
353,588856,1,1,,47193710,221493,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
354,602123,1,1,,47193710,221493,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
355,602141,1,1,,47193710,221493,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
356,602162,1,1,,47193710,221493,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
357,602163,1,1,,47193710,221493,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
358,602179,1,2,,47193710,221493,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
359,602229,1,1,,47193710,221493,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
360,602233,1,1,,47193710,221493,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
361,602244,1,2,,47193710,221493,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
362,602247,1,2,,47193710,221493,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
363,602248,1,2,,47193710,221493,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
364,602250,1,2,,47193710,221493,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
365,602252,1,1,,47193710,221493,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
366,602252,1,1,,47193710,221493,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
367,602261,1,1,,47193710,221493,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
368,602274,1,2,,47193710,221493,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
369,602281,1,1,,47193710,221493,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
370,602281,1,1,,47193710,221493,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
371,602310,1,2,,47193710,221493,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
372,602313,1,1,,47193710,221493,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
373,602329,1,1,,47193710,221493,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
374,602332,1,1,,47193710,221493,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
375,602340,1,2,,47193710,221493,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
376,602342,2,1,,47193710,221493,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
377,602346,1,1,,47193710,221493,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
378,602363,1,1,,47193710,221493,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
379,602393,1,1,,47193710,221493,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
380,602396,1,2,,47193710,221493,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
381,602399,1,2,,47193710,221493,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
382,602405,1,1,,47193710,221493,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
383,602410,1,1,,47193710,221493,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
384,602429,1,1,,47193710,221493,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
385,602438,1,1,,47193710,221493,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
386,602440,1,1,,47193710,221493,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
387,602449,1,2,,47193710,221493,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
388,602481,1,1,,47193710,221493,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
389,623870,1,1,,47193710,221493,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
390,623870,1,1,,47193710,221493,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
391,623877,1,1,,47193710,221493,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
392,623901,1,1,,47193710,221493,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
393,624037,1,3,,47193710,221493,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
394,624038,1,3,,47193710,221493,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
395,624040,1,3,,47193710,221493,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
396,624125,1,4,,47193710,221493,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
397,624126,1,3,,47193710,221493,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
398,624127,1,2,,47193710,221493,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
399,624168,1,1,,47193710,221493,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
400,624169,1,1,,47193710,221493,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
401,624170,1,1,,47193710,221493,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
402,624171,1,1,,47193710,221493,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
403,624172,1,1,,47193710,221493,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
404,624173,1,3,,47193710,221493,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
405,624178,1,1,,47193710,221493,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
406,624202,1,1,,47193710,221493,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
407,624204,1,2,,47193710,221493,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
408,624246,1,1,,47193710,221493,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
409,624256,1,2,,47193710,221493,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
410,624263,1,1,,47193710,221493,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
411,624263,1,1,,47193710,221493,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
412,624267,1,2,,47193710,221493,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
413,624267,1,2,,47193710,221493,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
414,624268,1,3,,47193710,221493,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
415,624288,1,1,,47193710,221493,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
416,624291,1,1,,47193710,221493,Inactive,121312.0,1081.0,,Potency,qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy,Confirmatory,,
417,624296,1,1,,47193710,221493,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
418,624297,1,1,,47193710,221493,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
419,624304,1,2,,47193710,221493,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
420,624330,1,2,,47193710,221493,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
421,624352,1,1,,47193710,221493,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
422,624354,1,1,,47193710,221493,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
423,624377,1,1,,47193710,221493,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
424,624416,1,1,,47193710,221493,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
425,624417,1,1,,47193710,221493,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
426,624418,1,1,,47193710,221493,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
427,624463,1,1,,47193710,221493,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
428,624464,1,1,,47193710,221493,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
429,624465,1,1,,47193710,221493,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
430,624466,1,3,,47193710,221493,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
431,624467,1,1,,47193710,221493,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
432,624483,1,1,,47193710,221493,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
433,624609,1,9,,103484622,221493,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
434,624612,1,9,,103484622,221493,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
435,624618,3,2,,103484622,221493,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
436,625144,5,5,,103484622,221493,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
437,625145,4,7,,103484622,221493,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
438,625146,5,5,,103484622,221493,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
439,625147,4,7,,103484622,221493,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
440,625148,4,7,,103484622,221493,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
441,625149,4,7,,103484622,221493,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
442,625150,5,5,,103484622,221493,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
443,625151,4,7,,103484622,221493,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
444,625152,4,7,,103484622,221493,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
445,625153,4,7,,103484622,221493,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
446,625154,4,7,,103484622,221493,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
447,625155,4,7,,103484622,221493,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
448,625156,1,9,,103484622,221493,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
449,625157,6,2,,103484622,221493,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
450,625158,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
451,625159,5,5,,103484622,221493,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
452,625160,1,9,,103484622,221493,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
453,625161,4,7,,103484622,221493,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
454,625162,4,7,,103484622,221493,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
455,625163,4,7,,103484622,221493,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
456,625164,1,6,,103484622,221493,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
457,625165,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
458,625166,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
459,625167,5,5,,103484622,221493,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
460,625168,4,7,,103484622,221493,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
461,625169,1,6,,103484622,221493,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
462,625170,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
463,625171,4,7,,103484622,221493,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
464,625172,4,7,,103484622,221493,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
465,625173,5,5,,103484622,221493,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
466,625174,5,5,,103484622,221493,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
467,625175,5,5,,103484622,221493,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
468,625176,1,9,,103484622,221493,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
469,625177,5,5,,103484622,221493,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
470,625178,5,5,,103484622,221493,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
471,625179,1,9,,103484622,221493,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
472,625180,5,5,,103484622,221493,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
473,625181,5,5,,103484622,221493,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
474,625182,5,5,,103484622,221493,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
475,625183,5,5,,103484622,221493,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
476,625184,5,5,,103484622,221493,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
477,625185,5,5,,103484622,221493,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
478,625186,5,5,,103484622,221493,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
479,625187,5,5,,103484622,221493,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
480,625188,1,9,,103484622,221493,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
481,625189,1,7,,103484622,221493,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
482,625190,4,5,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
483,625191,4,7,,103484622,221493,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
484,625192,4,7,,103484622,221493,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
485,625193,5,5,,103484622,221493,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
486,625194,4,7,,103484622,221493,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
487,625195,4,7,,103484622,221493,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
488,625196,5,6,,103484622,221493,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
489,625197,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
490,625198,4,7,,103484622,221493,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
491,625199,4,7,,103484622,221493,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
492,625200,4,7,,103484622,221493,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
493,625201,4,7,,103484622,221493,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
494,625202,4,7,,103484622,221493,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
495,625203,4,7,,103484622,221493,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
496,625204,4,7,,103484622,221493,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
497,625205,4,7,,103484622,221493,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
498,625206,4,7,,103484622,221493,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
499,625207,4,7,,103484622,221493,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
500,625208,5,5,,103484622,221493,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
501,625209,4,7,,103484622,221493,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
502,625210,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
503,625211,1,6,,103484622,221493,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
504,625212,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
505,625213,4,7,,103484622,221493,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
506,625214,1,9,,103484622,221493,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
507,625215,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
508,625216,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
509,625217,4,7,,103484622,221493,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
510,625218,4,7,,103484622,221493,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
511,625219,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
512,625220,4,7,,103484622,221493,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
513,625221,4,7,,103484622,221493,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
514,625222,4,7,,103484622,221493,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
515,625223,4,7,,103484622,221493,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
516,625224,3,4,,103484622,221493,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
517,625225,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
518,625226,4,7,,103484622,221493,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
519,625227,4,7,,103484622,221493,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
520,625228,4,7,,103484622,221493,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
521,625229,5,5,,103484622,221493,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
522,625230,1,6,,103484622,221493,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
523,625231,4,7,,103484622,221493,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
524,625232,1,9,,103484622,221493,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
525,625233,4,7,,103484622,221493,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
526,625234,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
527,625235,4,7,,103484622,221493,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
528,625236,5,5,,103484622,221493,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
529,625237,4,7,,103484622,221493,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
530,625238,4,7,,103484622,221493,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
531,625239,4,7,,103484622,221493,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
532,625240,1,9,,103484622,221493,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
533,625241,4,7,,103484622,221493,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
534,625242,4,7,,103484622,221493,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
535,625243,5,5,,103484622,221493,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
536,625244,5,5,,103484622,221493,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
537,625245,5,5,,103484622,221493,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
538,625246,1,9,,103484622,221493,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
539,625247,5,5,,103484622,221493,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
540,625248,5,5,,103484622,221493,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
541,625249,5,5,,103484622,221493,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
542,625250,5,5,,103484622,221493,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
543,625251,5,5,,103484622,221493,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
544,625252,4,7,,103484622,221493,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
545,625253,4,7,,103484622,221493,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
546,625254,4,7,,103484622,221493,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
547,625255,4,7,,103484622,221493,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
548,625256,4,7,,103484622,221493,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
549,625257,4,7,,103484622,221493,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
550,625258,4,7,,103484622,221493,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
551,625259,4,7,,103484622,221493,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
552,625260,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
553,625261,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
554,625262,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
555,625263,4,7,,103484622,221493,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
556,625264,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
557,625265,1,6,,103484622,221493,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
558,625266,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
559,625267,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
560,625268,4,2,,103484622,221493,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
561,625268,4,2,,103484622,221493,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
562,625268,4,2,,103484622,221493,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
563,625268,4,2,,103484622,221493,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
564,625269,4,7,,103484622,221493,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
565,625270,4,7,,103484622,221493,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
566,625271,5,5,,103484622,221493,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
567,625272,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
568,625273,4,6,,103484622,221493,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
569,625274,1,6,,103484622,221493,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
570,625275,3,4,,103484622,221493,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
571,651550,1,1,,47193710,221493,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
572,651560,1,1,,47193710,221493,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
573,651572,1,2,,47193710,221493,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
574,651602,1,1,,47193710,221493,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
575,651602,1,1,,47193710,221493,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
576,651602,1,1,,47193710,221493,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
577,651635,1,3,,47193710,221493,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
578,651636,1,1,,47193710,221493,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
579,651640,1,1,,47193710,221493,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
580,651644,1,1,,47193710,221493,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
581,651647,1,1,,47193710,221493,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
582,651654,1,1,,47193710,221493,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
583,651658,1,1,,47193710,221493,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
584,651661,2,1,,47193710,221493,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
585,651687,1,1,,47193710,221493,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
586,651699,1,1,,47193710,221493,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
587,651699,1,1,,47193710,221493,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
588,651702,1,2,,47193710,221493,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
589,651704,2,1,,47193710,221493,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
590,651710,1,1,,47193710,221493,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
591,651711,2,1,,47193710,221493,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
592,651718,1,2,,47193710,221493,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
593,651719,1,2,,47193710,221493,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
594,651723,1,1,,47193710,221493,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
595,651724,1,1,,47193710,221493,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
596,651725,1,1,,47193710,221493,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
597,651768,1,2,,47193710,221493,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
598,651800,1,1,,47193710,221493,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
599,651819,1,1,,47193710,221493,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
600,651820,1,1,,47193710,221493,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
601,651821,2,4,,47193710,221493,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
602,651957,1,1,,47193710,221493,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
603,651958,1,1,,47193710,221493,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
604,651965,1,1,,47193710,221493,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
605,651999,1,1,,47193710,221493,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
606,652010,1,1,,47193710,221493,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
607,652017,1,1,,47193710,221493,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
608,652025,1,1,,47193710,221493,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
609,652039,1,1,,47193710,221493,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
610,652048,1,2,,47193710,221493,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
611,652051,1,1,,47193710,221493,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
612,652054,1,1,,47193710,221493,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
613,652067,1,4,,47193710,221493,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
614,652104,1,1,,47193710,221493,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
615,652105,1,1,,47193710,221493,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
616,652106,1,1,,47193710,221493,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
617,652115,1,1,,47193710,221493,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
618,652126,1,3,,47193710,221493,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
619,652162,2,1,,47193710,221493,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
620,652163,1,1,,47193710,221493,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
621,652197,1,1,,47193710,221493,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
622,652257,1,1,,47193710,221493,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
623,657095,1,7,,103484622,221493,Active,262527527.0,8647.0,,,Restoration of wild type human BSEP trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as decrease in [3H]taurocholate accumulation at 10 to 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scintillation counting,Other,22464344.0,
624,657096,1,3,,103484622,221493,Unspecified,,,,,Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 100 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scintillation counting,Other,22464344.0,
625,657097,1,3,,103484622,221493,Unspecified,,,,,Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scintillation counting,Other,22464344.0,
626,662694,1,8,,103484622,221493,Inactive,46577705.0,9971.0,,,Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N at 10 uM by luciferase reporter gene assay,Other,22583617.0,
627,673744,3,1,,103484622,221493,Active,74762624.0,151306.0,13.6,EC50,Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis,Confirmatory,24900463.0,
628,673745,1,6,,103484622,221493,Unspecified,74762624.0,151306.0,,,Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis relative to 10 uM LCA,Other,24900463.0,
629,673746,3,1,,103484622,221493,Unspecified,46577705.0,9971.0,100.0,EC50,Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs,Confirmatory,24900463.0,
630,673747,1,6,,103484622,221493,Unspecified,46577705.0,9971.0,,,Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs relative to 10 uM CDCA,Other,24900463.0,
631,673748,1,3,,103484622,221493,Unspecified,,,,,Critical micelle concentration of the compound in 0.15 M NaCl water solution,Other,24900463.0,
632,673749,1,3,,103484622,221493,Unspecified,,,,,"1-Octanol/water partition coefficient, log P of the compound by conventional shake-flask method",Other,24900463.0,
633,673750,2,3,,103484622,221493,Unspecified,,,,,Aqueous solubility of the compound in 0.1 M HCl water at pH 3 by HPLC-ES-MS/MS,Other,24900463.0,
634,673751,1,6,,103484622,221493,Unspecified,113576.0,213.0,,,Binding affinity to albumin by equilibrium dialysis,Other,24900463.0,
635,686940,1,1,,47193710,221493,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
636,686964,1,1,,47193710,221493,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
637,686970,1,2,,47193710,221493,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
638,686971,1,2,,47193710,221493,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
639,686978,1,1,,47193710,221493,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
640,686979,1,1,,47193710,221493,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
641,686996,1,1,,47193710,221493,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
642,687014,1,1,,47193710,221493,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
643,687016,1,1,,47193710,221493,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
644,699539,1,7,,103484622,221493,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
645,699540,1,7,,103484622,221493,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
646,699541,1,7,,103484622,221493,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
647,720504,1,1,,47193710,221493,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
648,720508,1,1,,47193710,221493,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
649,720509,1,1,,47193710,221493,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
650,720511,1,1,,47193710,221493,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
651,720542,1,2,,47193710,221493,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
652,720543,1,1,,47193710,221493,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
653,720551,1,2,,47193710,221493,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
654,720553,1,2,,47193710,221493,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
655,720579,2,1,,47193710,221493,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
656,720580,1,1,,47193710,221493,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
657,720582,1,1,,47193710,221493,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
658,720596,1,1,,47193710,221493,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
659,720647,1,2,,47193710,221493,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
660,720648,1,1,,47193710,221493,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
661,720700,1,4,,47193710,221493,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
662,720702,1,1,,47193710,221493,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
663,720704,1,4,,47193710,221493,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
664,720706,1,2,,47193710,221493,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
665,720707,1,2,,47193710,221493,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
666,720708,1,2,,47193710,221493,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
667,720709,1,2,,47193710,221493,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
668,720711,1,2,,47193710,221493,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
669,743126,1,1,,47193710,221493,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
670,743255,1,1,,47193710,221493,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
671,743266,1,2,,47193710,221493,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
672,743269,1,1,,47193710,221493,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
673,743269,1,1,,47193710,221493,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
674,743279,1,2,,47193710,221493,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
675,743287,1,1,,47193710,221493,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
676,743398,1,1,,47193710,221493,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
677,933060,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020610,Other,,
678,933061,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020610",Other,,
679,933062,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020610,Other,,
680,933063,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020610,Other,,
681,933691,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020610,Other,,
682,933692,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020610,Other,,
683,933693,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020610,Other,,
684,933694,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020610,Other,,
685,933695,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020610,Other,,
686,933696,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020610,Other,,
687,933697,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020610,Other,,
688,933698,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020610,Other,,
689,933699,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020610,Other,,
690,933700,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020610,Other,,
691,933701,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020610,Other,,
692,933702,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020610,Other,,
693,933703,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020610,Other,,
694,933704,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020610,Other,,
695,933705,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020610,Other,,
696,945017,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020610,Other,,
697,945018,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020610,Other,,
698,945019,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020610,Other,,
699,945020,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020610,Other,,
700,945021,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020610,Other,,
701,945022,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020610,Other,,
702,945023,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020610,Other,,
703,945024,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020610",Other,,
704,945025,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020610,Other,,
705,945026,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020610,Other,,
706,945027,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020610,Other,,
707,945028,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020610,Other,,
708,945029,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020610,Other,,
709,945030,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020610,Other,,
710,945031,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020610,Other,,
711,945032,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020610,Other,,
712,945033,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020610,Other,,
713,945034,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020610,Other,,
714,945035,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020610,Other,,
715,966366,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020610,Other,,
716,966367,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020610,Other,,
717,966368,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020610,Other,,
718,966369,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020610,Other,,
719,966370,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020610,Other,,
720,966371,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020610,Other,,
721,966372,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020610,Other,,
722,966373,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020610,Other,,
723,966374,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020610,Other,,
724,966375,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020610,Other,,
725,966376,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020610,Other,,
726,966760,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020610,Other,,
727,966761,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020610,Other,,
728,966762,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020610,Other,,
729,966763,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020610,Other,,
730,966764,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020610,Other,,
731,966765,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020610,Other,,
732,966766,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020610,Other,,
733,966767,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020610,Other,,
734,968021,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020610,Other,,
735,968022,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020610,Other,,
736,968023,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020610,Other,,
737,968024,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020610,Other,,
738,968025,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020610,Other,,
739,968026,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020610,Other,,
740,968027,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020610,Other,,
741,968028,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020610,Other,,
742,968029,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020610,Other,,
743,976073,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020610,Other,,
744,976074,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020610,Other,,
745,976075,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020610,Other,,
746,976076,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020610,Other,,
747,976077,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020610,Other,,
748,976078,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020610,Other,,
749,976079,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020610,Other,,
750,976080,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020610,Other,,
751,976081,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020610,Other,,
752,976082,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020610,Other,,
753,977599,1,1,,103484622,221493,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
754,977602,1,2,,103484622,221493,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
755,1006984,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
756,1006985,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020610",Other,,
757,1006986,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020610",Other,,
758,1006987,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020610",Other,,
759,1006988,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020610",Other,,
760,1006989,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
761,1006990,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020610,Other,,
762,1006991,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020610",Other,,
763,1006992,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020610,Other,,
764,1006993,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020610",Other,,
765,1006994,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
766,1006995,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020610",Other,,
767,1006996,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020610",Other,,
768,1006997,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
769,1006998,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020610",Other,,
770,1006999,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020610",Other,,
771,1007000,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
772,1007001,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
773,1007002,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
774,1007003,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020610",Other,,
775,1007004,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
776,1007005,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
777,1007006,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
778,1007007,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
779,1007008,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020610",Other,,
780,1007009,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
781,1007010,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
782,1007011,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020610",Other,,
783,1007012,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
784,1007013,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020610,Other,,
785,1007014,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020610,Other,,
786,1007015,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020610",Other,,
787,1007596,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
788,1007597,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020610",Other,,
789,1007598,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020610,Other,,
790,1007599,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
791,1007600,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
792,1031520,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020610",Other,,
793,1031521,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020610",Other,,
794,1031522,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020610,Other,,
795,1031523,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
796,1031524,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020610",Other,,
797,1031525,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020610",Other,,
798,1031526,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
799,1031527,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
800,1031528,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020610",Other,,
801,1031529,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020610",Other,,
802,1031530,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020610",Other,,
803,1031531,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020610,Other,,
804,1031532,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
805,1031533,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020610",Other,,
806,1031534,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020610",Other,,
807,1031535,1,3,,103484622,221493,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020610,Other,,
808,1031536,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020610",Other,,
809,1031537,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020610",Other,,
810,1031538,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
811,1031539,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
812,1031540,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
813,1031541,1,3,,103484622,221493,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020610",Other,,
814,1053175,2,1,,124812307,221493,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
815,1053197,1,1,,47193710,221493,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
816,1059678,1,2,,103484622,221493,Active,,,,,Agonist activity at TGR5 N76A mutant (unknown origin),Other,24900622.0,
817,1059679,1,2,,103484622,221493,Inactive,,,,,Agonist activity at TGR5 S270A mutant (unknown origin),Other,24900622.0,
818,1059683,1,2,,103484622,221493,Active,,,,,Agonist activity at TGR5 E169A mutant (unknown origin),Other,24900622.0,
819,1059684,1,2,,103484622,221493,Inactive,,,,,Agonist activity at TGR5 N93A mutant (unknown origin),Other,24900622.0,
820,1059685,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 S270A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
821,1059686,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 Y89F mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
822,1059687,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 N76A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
823,1059688,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 Y89A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
824,1059689,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 E169A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
825,1059690,2,3,,103484622,221493,Active,74762624.0,151306.0,19.83,EC50,Agonist activity at wild type TGR5 (unknown origin),Confirmatory,24900622.0,
826,1059692,1,1,,103484622,221493,Unspecified,,,,,Selectivity ratio of EC50 for TGR5 N93A mutant (unknown origin) to EC50 for wild type TGR5 (unknown origin),Other,24900622.0,
827,1069886,1,1,,103484622,221493,Unspecified,,,,,Hemolytic activity in human erythrocytes assessed as release of hemoglobin at 0.75 mg/mL after 60 mins relative to control,Other,24461290.0,
828,1069888,1,1,,103484622,221493,Unspecified,,,,,Hemolytic activity in human erythrocytes assessed as increase in cell permeability up to 1 mg/mL after 60 mins,Other,24461290.0,
829,1117267,1,1,,47193710,221493,Inactive,48145933.0,7276.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of Transthyretin (TTR) transcription,Screening,,
830,1159524,1,1,,47193710,221493,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
831,1159550,3,1,,252401755,221493,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
832,1159606,1,1,,47193710,221493,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
833,1159620,1,1,,103484622,221493,Active,,,,,Summary of drug indications.,Other,,
834,1224865,1,2,,47193710,221493,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
835,1233552,1,1,,103484622,221493,Inconclusive,,,,IC50,Cytotoxicity against human WI38 cells by MTT assay,Confirmatory,26063305.0,
836,1233553,1,1,,103484622,221493,Inconclusive,,,,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms by microtiter plate based assay,Confirmatory,26063305.0,
837,1233559,1,1,,103484622,221493,Unspecified,,,132.7,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay,Confirmatory,26063305.0,
838,1233565,1,1,,103484622,221493,Inconclusive,,,,,Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 100 ug/ml by MTT assay,Other,26063305.0,
839,1233566,1,1,,103484622,221493,Unspecified,,,,,Cytotoxicity against human WI38 cells assessed as inhibition of cell growth at 20 ug/ml by MTT assay,Other,26063305.0,
840,1233567,1,1,,103484622,221493,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 100 ug/ml by microtiter plate based assay,Other,26063305.0,
841,1233568,1,1,,103484622,221493,Unspecified,,,,,Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms assessed as inhibition of parasite growth at 20 ug/ml by microtiter plate based assay,Other,26063305.0,
842,1233569,1,1,,103484622,221493,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 100 ug/ml by parasite lactate dehydrogenase assay,Other,26063305.0,
843,1233570,1,1,,103484622,221493,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as inhibition of parasite viability at 20 ug/ml by parasite lactate dehydrogenase assay,Other,26063305.0,
844,1247194,1,1,,103484622,221493,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 30 ug/ml by XRMA method relative to control",Other,26299346.0,
845,1247195,1,1,,103484622,221493,Unspecified,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 10 ug/ml by XRMA method relative to control",Other,26299346.0,
846,1247196,1,1,,103484622,221493,Inactive,,,,,"Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition at 3 ug/ml by XRMA method relative to control",Other,26299346.0,
847,1249117,1,1,,103484622,221493,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as effect on cell cycle phase at 100 uM by propidium iodide staining-based flow cytometry,Other,,
848,1259309,1,1,,124812307,221493,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
849,1259310,1,1,,321946804,221493,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
850,1259311,1,1,,124812307,221493,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
851,1259313,1,1,,47193710,221493,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
852,1259318,1,1,,47193710,221493,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
853,1259407,1,1,,363899576,221493,Inactive,,,,,CCRIS mutagenicity studies,Other,,
854,1259410,1,1,,363899576,221493,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
855,1259415,1,1,,47193710,221493,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
856,1259416,1,2,,340081896,221493,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
857,1259421,1,1,,340081896,221493,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
